Synonym
21-deacetyldeflazacort
IUPAC/Chemical Name
(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10-trimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d]oxazol-4-one
InChi Key
KENSGCYKTRNIST-RVUAFKSESA-N
InChi Code
InChI=1S/C23H29NO5/c1-12-24-23(18(28)11-25)19(29-12)9-16-15-5-4-13-8-14(26)6-7-21(13,2)20(15)17(27)10-22(16,23)3/h6-8,15-17,19-20,25,27H,4-5,9-11H2,1-3H3/t15-,16-,17-,19+,20+,21-,22-,23+/m0/s1
SMILES Code
CC1=N[C@@]2([C@@H](C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)O1)C(=O)CO
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
399.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ding W, Ding L, Li WB, Pan H, Lin HD. [Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers]. Yao Xue Xue Bao. 2014 Jun;49(6):921-6. Chinese. PubMed PMID: 25212041.
2: Patel DP, Sharma P, Patel BM, Sanyal M, Singhal P, Shrivastav PS. Analysis of 21-hydroxy deflazacort in human plasma by UPLC-MS/MS: application to a bioequivalence study in healthy volunteers. J Pharm Biomed Anal. 2013 Nov;85:213-7. doi: 10.1016/j.jpba.2013.07.035. Epub 2013 Aug 6. PubMed PMID: 23973630.
3: Ifa DR, Moraes ME, Moraes MO, Santagada V, Caliendo G, de Nucci G. Determination of 21-hydroxydeflazacort in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry. Application to bioequivalence study. J Mass Spectrom. 2000 Mar;35(3):440-5. PubMed PMID: 10767775.
4: Reynolds DL, Burmaster SD, Eichmeier LS. Quantitative determination of 21-hydroxy-deflazacort in human plasma using gradient semi-microbore liquid chromatography. Biomed Chromatogr. 1994 Sep-Oct;8(5):230-5. PubMed PMID: 7841767.
5: Santos-Montes A, Gonzalo-Lumbreras R, Gasco-Lopez AI, Izquierdo-Hornillos R. Extraction and high-performance liquid chromatographic separation of deflazacort and its metabolite 21-hydroxydeflazacort. Application to urine samples. J Chromatogr B Biomed Appl. 1994 Jul 1;657(1):248-53. PubMed PMID: 7952078.
6: Omote M, Sakai K, Mizusawa H. Acute effects of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions. Arzneimittelforschung. 1994 Feb;44(2):149-53. PubMed PMID: 7511903.
7: Langhoff E, Olgaard K. In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol. 1986 Feb;21(2):125-9. PubMed PMID: 3485440; PubMed Central PMCID: PMC1400905.
8: Russell JE, Gennari C, Imbimbo B, Avioli LV. Effects of deflazacort and the L-6485 metabolite on epiphyseal cartilage carbohydrate metabolism: comparison with prednisone. Horm Metab Res. 1985 Aug;17(8):402-5. PubMed PMID: 3840451.
